DGAP-Media / 24.01.2020 / 15:05
The surgical therapy of hollow organs in the abdomen (such as the bile duct or ureter) are challenges for the surgical team. Until today, the risk of defects happening that disable a regeneration of the anatomy were very high after a tumor or organ transplant. The necessary detour surgeries often lead to aftermath complications such as life-threatening infections, which cause longer hospital stays. The hope of many surgeons is to have a material that helps bridge long defects of hollow organs and leads to a regeneration reply and tissue regeneration.
Xlife Sciences AG
Xlife Sciences AG is a Swiss company with focus on investing in promising technologies in the life science industry. Xlife Sciences AG is building the bridge from research and development to healthcare markets. Together with industrial partners or universities, Xlife Sciences AG leads projects through the proof-of-concept phase after an invention disclosure or start-up. Subsequently, the firm focuses on out-licensing or selling the company, often with a combination of a strategic partnership. Xlife Sciences AG offers its investors direct access to the further development of innovative and future-oriented technologies at a very early stage.
End of Media Release
Issuer: Xlife Sciences AG
24.01.2020 Dissemination of a Press Release, transmitted by DGAP – a service of EQS Group AG.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Company:||Xlife Sciences AG|
|Phone:||0041 44 385 84 60|
|Listed:||Regulated Unofficial Market in Munich|
|EQS News ID:||960903|
|End of News||DGAP Media|